The latest price target for Processa Pharma (NASDAQ:PCSA) was reported by HC Wainwright & Co. on December 5, 2024. The analyst firm set a price target for $6.00 expecting PCSA to rise to within 12 months (a possible 605.97% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Processa Pharma (NASDAQ:PCSA) was provided by HC Wainwright & Co., and Processa Pharma reiterated their buy rating.

There is no last upgrade for Processa Pharma

The last downgrade for Processa Pharmaceuticals Inc happened on November 17, 2023 when Maxim Group changed their price target from N/A to N/A for Processa Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharma was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Processa Pharma (PCSA) rating was a reiterated with a price target of $6.00 to $6.00. The current price Processa Pharma (PCSA) is trading at is $0.85, which is out of the analyst’s predicted range.